Member Info for Polio

Gunsynd Plc

("Gunsynd" or the "Company")

Update on Barb Gold and Bear Twit Projects

Gunsynd (AIM: GUN) is pleased to provide an update in relation to Barb Gold Project and Bear Twit Project in Canada (together the "Projects"), in which the Company has a 100% legal and beneficial interest.

Barb Gold Project

Critical Discoveries has now been in the field for twelve days with an estimated nine days left in this field campaign. Numerous samples have been collected and work has mainly concentrated on identifying historic veins on the claims and identifying possible extensions and potential parallel structures.

Bear Twit Project

Assay results from the recently completed field program at Bear Twit have been sent to the lab and results are expected to be received in October 2025.

All good news

This may take a little time but we know what potential we have here and it won’t happen overnight.

Enjoy the ride, easy money to be made from here

Crawshaw it’s been a long week already, cannot be funday Thursday too 😂

Anyone else struggling to sleep!

Funday Friday is upon us and i can’t see this going other than blue

Get all your family and friends on this - this is 1000% going to the moon

Awesome news and still got my chunk in here

And still no crowd in here, it is going to take off sooner rather than later

Tomorrow is going to be epic. Wish I had more money to throw into this

Easy 15p coming up. We will get more than that within weeks

Literally so glad I have been busy all day as I think I would have sold up

100% here we come

I was so close to selling too and waiting 12 months now I’m

Buzzing again with more shares.

Do they have something in this company to reduce a heart attack

Let’s goooooooo this really should re rate now hahaha

Now it makes sense… was it a ploy to let people in on the cheap

Probably but so glad I picked more up

Yessssssssssssssss

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that, further to the Company's announcements dated 22 September 2025 regarding the Placing and Subscription which raised gross proceeds of £5.20 million, the Company has entered into an additional subscription agreement following inbound interest from a new institutional investor (the "Additional Subscription").

Pursuant to the terms of the Additional Subscription Agreement, ABRDN World Healthcare Fund has subscribed for 11,000,000 Subscription Shares at the Issue Price of 9.5 pence per share (the "Additional Subscription Shares") for an aggregate Subscription of £1.045 million ($1.410 million).

The funds raised via the Additional Subscription will further support the Company's commercial distribution efforts, which includes the recently announced collaboration with Tempus AI, Inc. (NASDAQ: TEM).

James McCullough, CEO of Renalytix, commented: "We are particularly pleased with the strong institutional support we have received at this critical time for accelerating growth with our U.S. kidneyintelX.dkd prognostic testing and unique data accumulation program in diabetes and kidney disease."

Yeeeehaaaaa 1 million at 9.5p

Agreed professor. I am not selling anything, not worth it

This is where this share will go

This has to explode just on what potential we have mate. All exciting stuff and hopefully we can come back hear and say we told you so

Nice

This is so under the radar